Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05180773 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05180773 · ClinicalTrials.gov record · last posted 2026-08-10

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Study acronym: REBIRTH
StatusRecruiting
PhasePhase 4
Started2022-07-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.

Protocol amendment history 1 change detected by DataLookout

2026-08-11
Primary completion pushed: 2026-06-30 → 2028-06-30
Trial Details
NCT Number NCT05180773
Lead Sponsor Dennis M. McNamara, MD, MS
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Peripartum Cardiomyopathy, Postpartum
Enrollment 250 participants
Start Date 2022-07-27
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10